Here, we report a novel combination with aminooxyacetic acid (AOA), a malate-aspartate shuttle (MAS) inhibitor, which enhances β-lap specific metabolic downregulation in NQO1+ breast cancer. The gene discussed is NQO1; the disease is breast cancer.